Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies

Mitchell, Paul; L McAllister, Ian; Larsen, Michael; Staurenghi, Giovanni; Korobelnik, Jean‐François; S. Boyer, David; Diana, V.; M. Brown, David; A. Katz, Todd; J. Berliner, Alyson; Vitti, Robert; Zeitz, Oliver; Metzig, Carola; Lu, Chengxing; G. Holz, Frank

doi:10.1016/j.oret.2018.02.011

Public

Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies

Published in Ophthalmology Retina • Mar 31, 2018

Authors:

Paul Mitchell

Ian L McAllister

Michael Larsen

Abstract

PURPOSE: To evaluate the impact of intravitreal aflibercept (EYLEA, Regeneron Pharmaceuticals, Tarrytown, NY) versus laser on progression of diabetic retinopathy (DR) severity in Intravitreal Aflibercept Injection in Vision Impairment due to DME (VIVID-DME) and Study of Intravitreal Aflibercept Inje...

Subject

Aflibercept

Medicine

Diabetic retinopathy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!